Apremilast, competitive inhibitor of phosphodiesterase 4 (PDE4), has been recently introduced in the treatment of adult PsA patients. Its efficacy and safety has been assessed in the Psoriatic Arthritis Long-term Assessment of Clinical Efficacy program, including four phase 3, multicentre, randomized, double-blind, placebo-controlled, parallelgroup trials. According to EULAR recommendations, US with power Doppler (PD) is able to detect joint inflammation and may be used to monitor PsA activity. Here, the US early response to apremilast in a PsA cohort was evaluated.

Early response to apremilast treatment in psoriatic arthritis: a real-life ultrasonographic follow-up study / Ceccarelli, Fulvia; Lucchetti, Ramona; Spinelli, Francesca Romana; Perricone, Carlo; Truglia, Simona; Miranda, Francesca; Scrivo, Rossana; Alessandri, Cristiano; Valesini, Guido; Conti, Fabrizio. - In: RHEUMATOLOGY. - ISSN 1462-0324. - STAMPA. - 57:8(2018), pp. 1490-1491-1491. [10.1093/rheumatology/key145]

Early response to apremilast treatment in psoriatic arthritis: a real-life ultrasonographic follow-up study

Ceccarelli, Fulvia;Lucchetti, Ramona;Spinelli, Francesca Romana;Perricone, Carlo;Truglia, Simona;Miranda, Francesca;Scrivo, Rossana;Alessandri, Cristiano;Valesini, Guido;Conti, Fabrizio
2018

Abstract

Apremilast, competitive inhibitor of phosphodiesterase 4 (PDE4), has been recently introduced in the treatment of adult PsA patients. Its efficacy and safety has been assessed in the Psoriatic Arthritis Long-term Assessment of Clinical Efficacy program, including four phase 3, multicentre, randomized, double-blind, placebo-controlled, parallelgroup trials. According to EULAR recommendations, US with power Doppler (PD) is able to detect joint inflammation and may be used to monitor PsA activity. Here, the US early response to apremilast in a PsA cohort was evaluated.
File allegati a questo prodotto
File Dimensione Formato  
Ceccarelli_ Apremilast_2018.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 82.02 kB
Formato Adobe PDF
82.02 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/1133398
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 8
social impact